Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MYC | P01106 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | QPCT | Q16769 | 1/20 | 0.56 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19303133 | 0.92 | KMT2A (0.67) | NAMPTCYP3A4KMT2AMEN1L3MBTL1 | |
| SCHEMBL21857890 | 0.90 | CYP3A4 (0.70) | NAMPTCYP3A4KMT2AMEN1L3MBTL1 | |
| SCHEMBL14082584 | 0.90 | NAMPT (0.59) | NAMPTCYP3A4KMT2AMEN1HDAC1 | |
| SCHEMBL14082282 | 0.86 | CYP3A4 (0.61) | NAMPTCYP3A4KMT2AMEN1MYC | |
| SCHEMBL21858046 | 0.82 | CYP3A4 (0.67) | NAMPTCYP3A4KMT2AMEN1L3MBTL1 | |
| SCHEMBL23535506 | 0.82 | CYP3A4 (0.59) | NAMPTCYP3A4KMT2AMEN1HDAC1 | |
| SCHEMBL14082155 | 0.81 | NAMPT (0.57) | NAMPTCYP3A4KMT2AMEN1MYC | |
| SCHEMBL5553234 | 0.80 | KMT2A (0.63) | NAMPTCYP3A4KMT2AMEN1MYC | |
| SCHEMBL14082463 | 0.78 | KMT2A (0.58) | NAMPTCYP3A4KMT2AMEN1HDAC1 | |
| SCHEMBL13403403 | 0.78 | KMT2A (0.61) | NAMPTCYP3A4KMT2AMEN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | NAMPT 527/4885CYP3A4 793/4885KMT2A 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.